Citigroup keeps Regeneron at neutral and raises price target to $825
Citigroup maintained its neutral rating on Regeneron Pharma shares and raised its price target to $825 from $740, Dow Jones Newswires reported.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reported that Citigroup kept its neutral rating on Regeneron Pharma while lifting its price target to $825 per share from $740 previously.
why it matters
For investors, a price target change from a major broker is one reference point when assessing the stock. The news concerns a single company and does not shift the broader market, so its significance is limited.
tags
instruments
sources
- Regeneron Pharma Is Maintained at Neutral by Citigroup — Dow Jones Newswires, 30 October 2026 at 22:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗